Atara biotherapeutics presents data demonstrating safety & sustained disability improvement at 12 months with ata188 in patients with progressive multiple sclerosis in late-breaking e-poster at the 2020 european academy of neurology virtual congress

Atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop treatment

ATRA Ratings Summary

ATRA Quant Ranking